These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32377764)

  • 1. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
    Ilhan H; la Fougère C; Krause BJ
    Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
    Plichta KA; Graves SA; Buatti JM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.
    Parsi M; Desai MH; Desai D; Singhal S; Khandwala PM; Potdar RR
    Med Oncol; 2021 Jun; 38(8):89. PubMed ID: 34181109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K; Turkbey B; Choyke PL
    Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
    Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
    Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.
    Naik M; Khan SR; Lewington V; Challapalli A; Eccles A; Barwick TD
    Br J Radiol; 2024 Aug; 97(1160):1391-1404. PubMed ID: 38733571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ; Lee SW; Ha HK
    Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
    Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
    Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
    Ceci F; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
    Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in prostate-specific membrane antigen PET of prostate cancer.
    Bouchelouche K; Choyke PL
    Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
    Miyahira AK; Soule HR
    J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Ferdinandus J; Violet J; Sandhu S; Hofman MS
    Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA Ligands for PET Imaging of Prostate Cancer.
    Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
    J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.